polyrizon-biotech.com (PLRZ): חובות להיוון בספרים

Polyrizon Ltd relies on the Capture and Block nasal gel patent portfolio, which ensures stable sales to clinics. The dynamics of the debt-to-book capitalization ratio confirm financial stability, where the 0.00 value serves as the baseline leverage indicator. Growth is driven by high-margin OTC sprays and bioprotection contracts, while the innovation vector is focused on laboratory tests of polymers for allergen blocking.

This indicator assesses the stability of the capital structure by comparing total liabilities to the book value of equity. The formula's dynamics are sensitive to daily fluctuations in the market valuation of assets, allowing for the prompt identification of bankruptcy risks. By analyzing the current leverage ratio based on book capital, an investor determines the degree of the business's financial autonomy. For Polyrizon Ltd (PLRZ), low metric values are driven by an outsourcing model. Foregoing capital expenditures in favor of contract manufacturing minimizes borrowings.